Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
ELVN Enliven Therapeutics
- 22.470
- -0.400-1.75%
Close Dec 20 16:00 ET
- 22.470
- 0.0000.00%
Post 16:20 ET
1.10BMarket Cap-12.46P/E (TTM)
22.990High21.830Low395.24KVolume22.510Open22.870Pre Close8.89MTurnover1.59%Turnover RatioLossP/E (Static)48.86MShares30.03052wk High3.81P/B558.68MFloat Cap10.90052wk Low--Dividend TTM24.86MShs Float250.840Historical High--Div YieldTTM5.07%Amplitude3.896Historical Low22.484Avg Price1Lot Size
About Enliven Therapeutics Company
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Company Profile
SymbolELVN
Company NameEnliven Therapeutics
Listing DateMar 12, 2020
Founded2019
CEOMr. Sam Kintz, M.B.A.
MarketNASDAQ
Employees46
Fiscal Year Ends12-31
Address6200 Lookout Road
CityBoulder
ProvinceColorado
CountryUnited States of America
Zip Code80301
Phone1-720-647-8519
Company Executives
- Name
- Position
- Salary
- Sam Kintz, M.B.A.
- President, Chief Executive Officer and Director
- 8.28M
- Dr. Anish Patel, Pharm.D.
- Chief Operating Officer
- --
- Benjamin Hohl
- Head of Corporate Development, Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Helen Collins, M.D.
- Chief Medical Officer
- 4.06M
- Dr. Richard Heyman, PhD
- Chairman of the Board
- 664.11K
- Dr. Lori Anne Kunkel, M.D.
- Director
- --
- Dr. Rahul D. Ballal, PhD
- Director
- 1.87M
- Dr. Andrew Phillips, PhD
- Independent Director
- 542.95K
- Dr. Mika Derynck, M.D.
- Independent Director
- 541.48K
- Jacob Bauer, M.B.A.
- Independent Director
- 551.21K
- Rishi Gupta, J.D.
- Independent Director
- 538.26K